Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating recombinant human vascular endothelial inhibitor in combination with PRaG for advanced refractory non-smal…
-
CLINICAL_TRIALS trial_result · 2023-09-18Clinical Trial Update: Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 trial comparing dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations [Phase 2]
Phase 2 trial updating activity of molecularly matched targeted therapies across select tumor types based on genomic alterations; study comp…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations [Phase 2]
Phase 2 clinical trial evaluating the combination of sintilimab and anlotinib in advanced non-small cell lung cancer with EGFR uncommon muta…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens [Phase 1, Phase 2]
Phase 1/2 trial update of a personalized cancer vaccine targeting shared neoantigens for solid tumors including non-small cell lung cancer a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial of pembrolizumab combined with Itacitinib (INCB039110) for non-small cell lung cancer was terminated; results posted previousl…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study of a Personalized Neoantigen Cancer Vaccine [Phase 1, Phase 2]
Clinical trial update for a personalized neoantigen cancer vaccine completed across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy [Phase 3]
A Phase 3 clinical trial updates the use of radiotherapy in combination with immune checkpoint inhibitors for locally advanced non-small cel…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) [Phase 3]
Phase 3 clinical trial investigating selective lymph node dissection for early-stage invasive non-small cell lung cancer (cT1N0M0, CTR>0.5) …
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations [Phase 2]
Phase 2 clinical trial update evaluating neratinib tablets for advanced non-small cell lung cancer with rare EGFR mutations.
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy [Phase 2]
Phase 2 trial investigating lazertinib in combination with chemotherapy for EGFR-mutant non-small cell lung cancer after incomplete response…
-
CLINICAL_TRIALS trial_result · 2023-09-01Clinical Trial Update: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy [Phase 2]
Phase 2 trial evaluating lazertinib as consolidation therapy after chemoradiation in locally advanced, unresectable EGFR-mutant non-small ce…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: The Efficacy and Safety of KN046 Combined With Axitinib [Phase 2, Phase 3]
Clinical trial update on KN046 with axitinib for non-small cell lung cancer (NSCLC) across Phase 2 and Phase 3, with status currently UNKNOW…
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC [Phase 2]
Phase 2 trial evaluating bevacizumab with fractionated stereotactic radiotherapy for 1 to 10 brain metastases from non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread [Phase 1, Phase 2]
Phase 1/2 trial investigating BMS-986205 with nivolumab alone and with nivolumab plus ipilimumab in advanced cancers, including melanoma and…
-
CLINICAL_TRIALS trial_result · 2023-08-25Clinical Trial Update: Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI [Phase 2]
Phase II study of SY-3505 in ALK-positive non-small cell lung cancer patients after failure of prior second-generation ALK inhibitors is ong…
-
CLINICAL_TRIALS trial_result · 2023-08-24Clinical Trial Update: Folinic Acid for Prevention of Pemetrexed-induced Toxicity [Phase 4]
Phase 4 trial update evaluating folinic acid to prevent pemetrexed-induced toxicity in NSCLC, mesothelioma, and thymoma.
-
CLINICAL_TRIALS trial_result · 2023-08-23Clinical Trial Update: A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment [Phase 2]
Phase 2 trial evaluating toripalimab with pemetrexed and carboplatin in EGFR-mutant, T790M-negative NSCLC after progression on EGFR-TKI ther…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Phase 1/2 trial evaluating M7824 in combination with chemotherapy for stage IV non-small cell lung cancer has completed with results posted …
-
CLINICAL_TRIALS trial_result · 2023-08-18Clinical Trial Update: APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma [Phase 1]
Phase 1 trial of APX005M in combination with nivolumab and cabiralizumab in advanced melanoma, non-small cell lung cancer, and renal cell ca…
-
CLINICAL_TRIALS trial_result · 2023-08-18Clinical Trial Update: Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating video-assisted surgery for treating non-small cell lung cancer has been completed.
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib [Phase 2]
Phase 2 clinical trial update for X-396 capsule in ALK-positive non-small cell lung cancer patients previously treated with crizotinib.
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC [Phase 3]
Phase 3 trial evaluating camrelizumab plus famitinib as subsequent therapy in advanced NSCLC was terminated.
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating AK104/Tislelizumab plus chemotherapy as first-line treatment in PD-L1 TPS < 1% non-small cell lung cancer, currentl…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC [Phase 2]
Phase 2 clinical trial investigating furmonertinib as neoadjuvant therapy for resectable stage II–IIIb EGFR-sensitive mutant non-small cell …